

# Biological evaluation of medical devices

## Part 16: Toxicokinetic study design for degradation products and leachables (ISO 10993-16:1997)

ICS 11.100.20

National foreword

This British Standard is the UK implementation of EN ISO 10993-16:2009. It is identical to ISO 10993-16:1997. It supersedes BS EN ISO 10993-16:1997 which is withdrawn.

The UK participation in its preparation was entrusted to Technical Committee CH/194, Biological evaluation of medical devices.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

**Compliance with a British Standard cannot confer immunity from legal obligations.**

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 31 July 2009.  
© BSI 2009

ISBN 978 0 580 65824 2

Amendments/corrigenda issued since publication

Date	Comments

English Version

**Biological evaluation of medical devices - Part 16: Toxicokinetic  
study design for degradation products and leachables (ISO  
10993-16:1997)**

Évaluation biologique des dispositifs médicaux - Partie 16:  
Conception des études toxicocinétiques des produits de  
dégradation et des substances relargables (ISO 10993-  
16:1997)

Biologische Beurteilung von Medizinprodukten - Teil 16:  
Entwurf und Auslegung toxikokinetischer Untersuchungen  
hinsichtlich Abbauprodukten und Extrakten (ISO 10993-  
16:1997)

This European Standard was approved by CEN on 12 April 2009.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION  
COMITÉ EUROPÉEN DE NORMALISATION  
EUROPÄISCHES KOMITEE FÜR NORMUNG

**Management Centre: Avenue Marnix 17, B-1000 Brussels**

## Foreword

The text of ISO 10993-16:1997 has been prepared by Technical Committee ISO/TC 194 "Biological evaluation of medical devices" of the International Organization for Standardization (ISO) and has been taken over as EN ISO 10993-16:2009 by Technical Committee CEN/TC 206 "Biological evaluation of medical devices" the secretariat of which is held by NEN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by October 2009, and conflicting national standards shall be withdrawn at the latest by March 2010.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 10993-16:1997.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directives 93/42/EEC on Medical Devices and 90/385/EEC on Active Implantable Medical Devices.

For relationship with the EU Directives, see informative Annexes ZA and ZB, which is an integral part of this document.

According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.

### Endorsement notice

The text of ISO 10993-16:1997 has been approved by CEN as a EN ISO 10993-16:2009 without any modification.

## Annex ZA

(informative)

### Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC on Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Essential Requirements of the New Approach Directive 93/42/EEC on medical devices.

Once this standard is cited in the Official Journal of the European Communities under that Directive and has been implemented as a national standard in at least one Member State, compliance with the clauses of this standard given in table ZA confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding Essential Requirements of that Directive and associated EFTA regulations.

**Table ZA — Correspondence between this European Standard and Directive 93/42/EEC on medical devices**

Clause(s)/sub-clause(s) of this EN	Essential Requirements (ERs) of Directive 93/42/EEC	Qualifying remarks/Notes
4, 5 & Annex A	Annex I: 7.1, 7.2, 7.5	

**WARNING —** Other requirements and other EU Directives may be applicable to the product(s) falling within the scope of this standard.

## Annex ZB (informative)

### Relationship between this European Standard and the Essential Requirements of EU Directive 90/385/EEC on Active Implantable Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Essential Requirements of the New Approach Directive 90/385/EEC on active implantable medical devices.

Once this standard is cited in the Official Journal of the European Communities under that Directive and has been implemented as a national standard in at least one Member State, compliance with the clauses of this standard given in table ZB confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding Essential Requirements of that Directive and associated EFTA regulations.

**Table ZB — Correspondence between this European Standard and Directive 90/385/EEC on active implantable medical devices**

Clause(s)/sub-clause(s) of this EN	Essential Requirements (ERs) of Directive 90/385/EEC	Qualifying remarks/Notes
4, 5 & Annex A	Annex I : 9	

**WARNING** — Other requirements and other EU Directives may be applicable to the product(s) falling within the scope of this standard.

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

International Standard ISO 10993 was prepared by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*.

ISO 10993 consists of the following parts, under the general title *Biological evaluation of medical devices*:

- *Part 1: Evaluation and testing*
- *Part 2: Animal welfare requirements*
- *Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity*
- *Part 4: Selection of tests for interactions with blood*
- *Part 5: Tests for cytotoxicity: in vitro methods*
- *Part 6: Tests for local effects after implantation*
- *Part 7: Ethylene oxide sterilization residuals*
- *Part 9: Framework for the identification and quantification of potential degradation products [Technical Report]*
- *Part 10: Tests for irritation and sensitization*
- *Part 11: Tests for systemic toxicity*
- *Part 12: Sample preparation and reference materials*
- *Part 13: Identification and quantification of degradation products from polymers*
- *Part 14: Identification and quantification of degradation products from ceramics*
- *Part 15: Identification and quantification of degradation products from metals and alloys*
- *Part 16: Toxicokinetic study design for degradation products and leachables*

Future parts will deal with other relevant aspects of biological testing.

Annex A forms an integral part of this part of ISO 10993. Annex B is for information only.

## Introduction

This part of ISO 10993 provides guidance and requirements on the design and performance of toxicokinetic studies.

Toxicokinetics describes the absorption, distribution, metabolism and excretion of foreign compounds in the body with time. Essential to the evaluation of the safety of a medical device is consideration of the stability of the material(s) *in vivo* and the disposition of leachables and degradation products. Toxicokinetic studies may be of value in assessing the safety of materials used in the development of a medical device or in elucidating the mechanism of observed adverse reactions. The need for and extent of such studies should be carefully considered based on the nature and duration of contact of the device with the body.

The potential hazard posed by a medical device may be attributed to the interactions of its components or their metabolites with the biological system. Medical devices may release leachables (e.g. residual catalysts, processing aids, residual monomers, fillers, antioxidants, plasticizers) and/or degradation products which migrate from the material and have the potential to cause adverse effects in the body.

A considerable body of published literature exists on the use of toxicokinetic methods to study the fate of chemicals in the body (see annex B). The methodologies and techniques utilized in such studies form the basis of the guidance in this standard. A rationale for the use of this part of ISO 10993 is given in annex A.

iv



# Biological evaluation of medical devices —

## Part 16:

### Toxicokinetic study design for degradation products and leachables

## 1 Scope

This part of ISO 10993 gives principles on how toxicokinetic studies relevant to medical devices should be designed and performed. Annex A describes the considerations for inclusion of toxicokinetic studies in the biological evaluation of medical devices.

## 2 Normative reference

The following standard contains provisions which, through reference in this text, constitute provisions of this part of ISO 10993. At the time of publication, the edition indicated was valid. All standards are subject to revision, and parties to agreements based on this part of ISO 10993 are encouraged to investigate the possibility of applying the most recent edition of the standard indicated below. Members of IEC and ISO maintain register of currently valid International Standards.

ISO 10993-1:1992, *Biological evaluation of medical devices — Part 1: Guidance on selection of tests*.

## 3 Definitions

For the purposes of this part of ISO 10993, the definitions given in ISO 10993-1 and the following definitions apply.

**3.1 degradation product:** Product of a material which is generated by the chemical breakdown or decomposition of the material.

**3.2 leachable:** Extractable component, such as an additive, monomeric or oligomeric constituent of polymeric material.

**3.3 test substance:** Degradation product or leachable used for toxicokinetic study.

**3.4 absorption:** Process by which a substance enters the blood and/or lymph system.

**3.5 distribution:** Process by which an absorbed substance and/or its metabolites circulate and partition within the body.

**3.6 metabolism:** Process by which an absorbed substance is structurally changed within the body by chemical and/or enzymatic reactions.

**NOTE —** The products of the initial reaction may subsequently be modified by either enzymatic or non-enzymatic reactions prior to excretion.

**3.7 excretion:** Process by which an absorbed substance and/or its metabolites are removed from the body.

**3.8 bioavailability:** Extent of systemic absorption of intact substance.

**3.9 clearance:** Rate of removal of a substance from the body by metabolism and/or excretion.

**3.10 half-life ( $t_{1/2}$ ):** Time for the concentration of a particular molecular species to decrease to 50% of its initial value in the same body fluid or tissue.

**3.11 mean residence time:** Statistical moment related to half-life which provides a quantitative estimate of the persistence of a substance in the body.

**3.12  $c_{\max}$ :** Maximum concentration of a substance in plasma expressed in mass per unit volume.

NOTE – When the maximum concentration in fluid or tissue is being referred to, it should have an appropriate identifier e.g.  $c_{\max, \text{liver}}$  and be expressed in mass per unit volume or mass.

**3.13  $t_{\max}$ :** Time at which  $c_{\max}$  is observed.

**3.14  $AUC_{0-t}$ :** Area under the plasma concentration versus time curve, from time zero to time  $t$  following a single dose of a substance.

NOTE –  $t$  is normally extrapolated to infinity.

**3.15  $AUMC_{0-t}$ :** Area under the first moment plasma concentration versus time curve, from time zero to time  $t$  following a single dose of a substance.

NOTE –  $t$  is normally extrapolated to infinity.

**3.16 volume of distribution ( $V_d$ ):** Parameter for a single-compartment model describing the apparent volume which would contain the amount of test substance in the body if it were uniformly distributed.

**3.17 extract liquid:** Liquid which is the result of the extraction process on the test material.

**3.18 biodegradation:** Alteration of a medical device or biomaterial involving loss of integrity and/or performance when exposed to a physiological or simulated environment.

**3.19 bioresorption:** Process by which a biomaterial is degraded in the physiological environment and the product(s) eliminated and/or absorbed.

## 4 Principles for design of toxicokinetic studies

**4.1** Toxicokinetic studies should be designed on a case-by-case basis.

**4.2** A study protocol shall be written prior to commencement of the study. The study design, including methods, shall be defined in this protocol. Details of areas to be defined are given below and in clause 5.

**4.3** The results of leaching studies should be considered in order to determine the methods to be used for toxicokinetic studies. Information on the chemical and physicochemical properties, surface morphology of the material and biochemical properties of any leachable should also be considered.

NOTE – The extent and rate of release of leachables depend on the concentration at the surface, migration to the surface within the material, solubility and flowrate in the physiological milieu.

**4.4** It is recommended to undertake toxicokinetic studies with a characterized leachable or degradation product which has the potential of being toxic. However, the performance of toxicokinetic studies on mixtures is possible under certain conditions. An extract liquid (see ISO 10993-12), or a ground or powdered

form of the material or device, may be used in exceptional circumstances and shall be justified in the study design.

**4.5** Analytical methods shall be able to detect and characterize degradation products, leachables and metabolites in biological fluids and tissues. They shall be fully described in the study report (see 5.1.11). Quantitative analytical methods shall be specific, sensitive and reproducible, and produce data which show linearity over the range of expected analyte concentrations. Validation of the assay method shall be presented in the report.

**4.6** The study design shall state the physiological fluid, tissue or excreta in which analyte levels will be determined.

**NOTE** – Blood is convenient to sample and thus is often the fluid of choice for kinetic parameter and absorption studies. It is necessary to specify whether analysis is on whole blood, serum or plasma and to provide validation of this choice. Binding to circulating proteins or red cells can be determined *in vitro*.

**4.7** The study report should contain information on analyte binding in the sample (e.g. amount and affinity) and demonstrate that this does not lead to underestimation of analyte concentration.

**4.8** There should be sufficient data points with adequate spacing to allow determination of kinetic parameters. In theory this should cover several terminal half-lives; in practice the constraints of the analytical method may necessitate a compromise.

## 5 Guidance on test methods

### 5.1 General considerations

**5.1.1** The study should be performed in an appropriate sex and species. Healthy young adult animals should be acclimatized to laboratory conditions for at least 7 days. They should be transferred to individual metabolism cages, when used, for an acclimatization period of at least 24 h. The environmental conditions should be as recommended in guidelines for the care and use of animals (see ISO 10993-2). During the study conventional animal diets and drinking water should be freely available unless otherwise specified in the protocol. Animals should be randomly selected into groups for each time period studied; group sizes of at least three for small animals and at least two for larger species should be used. At the appropriate specified times, animals should be humanely killed.

**5.1.2** A non-radiolabelled test substance may be utilized providing suitable validated assay procedures for the test substance in the relevant samples exist and the metabolism of the test substance is well characterized.

**5.1.3** If necessary the test substance should be radiolabelled in a metabolically stable position, preferably with  $^{14}\text{C}$  or  $^3\text{H}$ , and of a suitable radiochemical purity (>97%). When using  $^3\text{H}$ , the possibility of tritium exchange should be considered. The radiolabelled compound should be diluted, when appropriate, with non-radiolabelled substance.

**5.1.4** When using a radiolabelled compound, the specific activity and radiochemical purity of the test substance shall be known.

**5.1.5** The test substance should be administered by an appropriate route. This route should be relevant to the use of the medical device. The test substance should be prepared in a suitable sample appropriate to the route of dose administration. The stability of the sample under the proposed conditions of administration should be known and reported.

**NOTE** – The study design may require the inclusion of other route(s) for comparison.

**5.1.6** In dose balance studies, animals should be housed only in metabolism cages.

**5.1.7** Urine and faeces should be collected in low temperature vessels (or in vessels containing preservative not interfering with the analysis) to prevent post-elimination microbial or spontaneous modification. Blood for whole-blood or plasma analysis should be collected in the presence of a suitable anticoagulant.

**5.1.8** Controls should, wherever possible, be collected prior to dosing. In some studies collection of controls (e.g. tissues) is not possible from the test animals and these should be obtained from a control group.

**5.1.9** Collection times should be appropriate to the type of study being performed, and may be carried out, as necessary, over periods of minutes, hours, days, weeks or even months. For studies involving excreta, this is usually 24-h periods over at least 96 h. Where blood sampling is required, blood is collected according to a specified schedule ranging from minutes to hours over a period up to 72 h.

**5.1.10** Toxicokinetic studies should be performed according to appropriate good laboratory practice.

**5.1.11** The study report shall include the following information, where relevant:

- a) strain and source of animals, environmental conditions, diet, age, sex;
- b) test substance and sample, purity, stability, formulation, amount administered;
- c) test conditions, including route of administration;
- d) assay methods, extraction, detection, validation;
- e) overall recovery of material;
- f) tabulation of individual results at each time point;
- g) quality standard or good laboratory practice compliance statement;
- h) discussion of results;
- i) interpretation of results.

## **5.2 Guidance on specific types of test**

### **5.2.1 General**

The study should be designed to provide the necessary information for risk assessment, and therefore it is usually not necessary to examine all aspects.

**5.2.1.1** Absorption, distribution, metabolism and excretion studies are a range of studies capable of being performed either individually, examining one of these aspects, or collectively, examining several aspects in one study.

**5.2.1.2** Depending on the design of the study, a number of kinetic parameters may be determined including absorption rate, elimination rate,  $AUC_{0-t}$ ,  $AUMC_{0-t}$ ,  $c_{max}$ ,  $t_{max}$ , half-life, mean residence time, volume of distribution and clearance.

**5.2.1.3** Kinetic parameters can only be determined for a particular molecular species and hence the assay needs to be specific and sensitive to this molecular species. True kinetic parameters of a relevant compound can only be determined following intravenous administration. It may therefore be necessary to include a limited intravenous administration study in the design of the kinetic parameter studies. This allows the fraction of the dose absorbed to be calculated and this serves as a correction in estimating parameters in other studies.

**5.2.1.4** The appropriate kinetic model should be used in determining the kinetic parameters. A number of computer programs exists for estimating kinetic parameters. The software should be validated prior to use and this validation should be documented. The assumptions entered into the program and the choices in modelling should be documented.

### 5.2.2 Absorption

Absorption depends on the route of administration, the physicochemical form of the test substance and the vehicle. It can be estimated from blood, serum, excreta and tissue concentrations. Complete bioavailability studies may be considered. The choice of the appropriate type of study depends on the other information required, availability of radiolabelled material and assay method. In a kinetic parameter study, the absorption rate constant can be estimated reliably only if sufficient samples are taken in the absorption phase.

NOTE – *In vitro* methods exist which may give important information on gastrointestinal and dermal absorption of chemicals.

### 5.2.3 Distribution

5.2.3.1 Distribution studies generally require radiolabelled compound. Studies may be

- quantitative, determining levels in dissected tissues,
- qualitative, using whole-body autoradiography (WBA),
- semiquantitative, using graded WBA standards.

5.2.3.2 In general, sampling times in distribution studies should be  $t_{\max}$ , 24 h and 168 h or longer, depending on test substance elimination. Intermediate times may be used when these additional data are required. Sampling is normally more frequent in the early phase of absorption and elimination; however samples need to be obtained over as much of the elimination phase as possible (ideally 3 to 4 half-lives) to provide the best estimates of kinetic parameters. The major determinant is often assay sensitivity.

### 5.2.4 Metabolism and excretion

5.2.4.1 Metabolism cages should permit separate collection of urine and faeces throughout the study. For studies of up to 14 days, the urine and faeces should be individually collected at 24 h and then every 24 h until the end of the experiment. In some study designs, animals may be sacrificed at intermediate times. Samples may be collected prior to 24 h when it is probable that the test substance or its metabolites will be rapidly excreted. For studies of longer duration, sampling over the initial period should occur as for the short-term studies. Thereafter samples should be obtained for a continuous 24 h period per assessment period.

NOTE – The use of metabolism cages for prolonged periods may be detrimental to animal welfare. Therefore at the longer times, representative discontinuous samples may be collected and these results extrapolated to continuous sampling.

5.2.4.2 The carcasses and/or target organs of the individual animals should be retained for analysis, and blood collected for analysis of plasma and whole-blood concentrations. After collection of the samples from the metabolism cages at the sacrifice time, the cages and their traps should be washed with an appropriate solvent. The resulting washes can be pooled and a representative fraction retained for analysis.

5.2.4.3 The recovery or calculated recovery of test substance should ideally be  $(100 \pm 10)\%$  when radiolabelled compound is used (see the note below). The amount of test substance in each fraction should be analysed by suitably validated procedures for either radiolabelled or non-radiolabelled compound in the appropriate milieu. Where a radiolabelled compound is used, both parent compound and metabolites are assessed, unless a specific assay is used. If the radiolabelled compound cannot be sufficiently recovered in the excreta (faeces and/or urine) or in the body, collection of expired air should be considered.

NOTE – The recovery range specified may not be achievable in all cases, and reasons for any deviation should be stated and discussed in the report.

5.2.4.4 Levels of radioactivity in the biological milieu should be determined, for example by liquid scintillation counting; however it must be stressed that this represents a mixed concentration of compound

and metabolites, and no kinetic parameters can be derived from it. Where isolation of metabolites is considered necessary, this may involve a number of extractions and chromatographic procedures (e.g. high-pressure liquid chromatography, thin layer chromatography, gas-liquid chromatography), and the resulting material should be characterized by chemical methods and a variety of physical chemistry techniques (e.g. mass spectrometry, nuclear magnetic resonance spectroscopy).

NOTE – The use of tissues, cells, homogenates and isolated enzymes for the study of metabolism *in vitro* is well documented. These methods identify potential metabolism which may not occur *in vivo* unless the compound is available at the appropriate site. The extents and rates of metabolism *in vitro* compared to *in vivo* will often differ.

## Annex A

(normative)

### Circumstances in which toxicokinetic studies shall be considered

**A.1** Potential hazards exist in the use of most medical devices. However, it is neither necessary nor practical to conduct toxicokinetic studies for all identifiable degradation products and leachables, nor for all medical devices.

**A.2** The need for toxicokinetic studies as part of the biological evaluation of a medical device shall be considered taking into account the final product and its constituent chemicals, including potential and designed degradation products and leachables in combination with the intended use of the device.

**A.3** Where appropriate, theoretical degradation processes should be investigated prior to toxicokinetic studies by means of *in vitro* experiments (e.g. tissue, homogenates or cells), not only for animal welfare reasons as given in ISO 10993-2, but also to determine probable rather than possible degradation products.

**A.4** Toxicokinetic studies shall be considered if

- a) the device is designed to be bioresorbable, or
- b) the device is a permanent contact implant, and biodegradation or significant corrosion is known or likely, and/or migration of leachables from the device occurs, or
- c) substantial quantities of potentially toxic or reactive degradation products and leachables are likely or known to be released from a medical device into the body during clinical use.

NOTE – The meaning of the term "substantial quantities" is dependent on the properties of the chemicals in question.

**A.5** Toxicokinetic studies are not required to be considered if

- a) the achieved or expected rates of release of degradation products and leachables from a particular device or material have been adjudged to provide safe levels of clinical exposure following reference to significant historical experience, or
- b) sufficient toxicological data or toxicokinetic data relevant to the degradation products and leachables already exist.

**A.6** The release of leachables and degradation products from metals, alloys and ceramics is usually too low to justify toxicokinetic studies.

## Annex B

### (informative)

### Bibliography

- [1] ISO 10993-2:1992, *Biological evaluation of medical devices - Part 2: Animal welfare requirements*.
- [2] ISO 10993-12:1996, *Biological evaluation of medical devices - Part 12: Sample preparation and reference materials*.
- [3] ANDERSEN M.E, CLEWELL H.J. III, GARGAS M.L., SMITH F.A. and REITZ R.H. Physiologically-based pharmacokinetics and the risk assessment process for methylene chloride. *Toxicol. Appl. Pharmacol.* **54**:100-116; 1987.
- [4] BOGEN D.K. Simulation software for the Macintosh. *Science* **24**:138-142; 1989.
- [5] F.D.A. Guidelines for the format and content of the human pharmacokinetics and bioavailability section of an application. Department of Health and Human Services.
- [6] HATTIS D., WHITE P., MAMORSTEIN L. and KOCH P. Uncertainties in pharmacokinetic modelling for perchloroethylene. I. Comparison of model structure, parameters and predictions for low-dose metabolism rates derived by different authors. *Risk Analysis* **10**:449-458, 1990.
- [7] International Programme on Chemical Safety (IPCS). Principles of toxicokinetic studies. *Environmental Health Criteria* **57**, World Health Organization, Geneva, 1986.
- [8] ISO/TR 10993-9:1994 *Biological evaluation of medical devices - Part 9: Degradation of materials related to biological testing*.
- [9] JOLLOW D.J., ROBERTS S., PRICE V., LONGACRE S. and SMITH C. Pharmacokinetic considerations in toxicity testing. *Drug Metab. Rev.* **13**:983-1007, 1982.
- [10] KATZPER M. The use of visual programming for pharmacokinetic and pharmacodynamic simulation. *Centre for Drug Evaluation and Research*, FDA, 5600 Fishers Lane, Rockville MD 20857
- [11] LIN C.S., SHOAF S.E., and GRIFFITHS J.C. Pharmacokinetic data in the evaluation of the safety of food and colour additives. *Reg. Toxicol. Pharmacol.* **15**:62-72, 1992.
- [12] MONRO A.M. Interspecies comparisons in toxicology: The utility and futility of plasma concentrations of the test substance. *Reg. Toxicol. Pharmacol.* **12**:137-160, 1990.
- [13] Organization for Economic Cooperation and Development (OECD). Guidelines for testing of chemicals - No 417 *Toxicokinetics*. OECD Publications.
- [14] REITZ R. Distribution, persistence and elimination of toxic agents. In: *Progress in Predictive Toxicology*. Clayson D B *et al.* (eds.), Elsevier, New York, 1990.
- [15] ROWLAND M. and TOZER T.N. *Clinical pharmacokinetics: concepts and applications* (2<sup>nd</sup> edition). Lea and Febiger, Philadelphia, 1989.
- [16] SMITH D.A., HUMPHREY M.J and CHARUEL C. Design of toxicokinetic studies. *Xenobiotica* **20**:1187-1199, 1990.



- [17] SPEID L.H., LUMLEY C.E. and WALKER S.R. Harmonisation of guidelines for toxicity testing of pharmaceuticals by 1992. *Reg. Toxicol. Pharmacol* **12**:179-211, 1990.
- [18] TRAVIS C.B. Pharmacokinetics. In: *Carcinogen Risk Analysis*. Traves C.B (ed) Contemporary issues. in risk analysis, vol. 3, Plenum Press, New York, 1988.
- [19] WAGNER J.G. *Pharmacokinetics for pharmaceutical scientists*. Technomic publishing Co. Inc., Lancaster, 1994.
- [20] WARTAK J. Clinical Pharmacokinetics, A modern approach to individualised drug therapy. *Clinical Pharmacology and Therapeutics Series*, Vol. 2. Praeger Publishers CBS Educational and Professional Publishing, 1983.
- [21] WEISSINGER J. Nonclinical pharmacologic and toxicologic considerations for evaluating biologic products. *Reg. Toxicol. Pharmacol.* **10**:255-263, 1989.
- [22] WELLING P.G. Pharmacokinetic processes and mathematics. *ACS Monograph 185*. American Chemical Society, Washington DC, 1986.
- [23] WELLING P.G., DE LA IGLESIA F.A. *Drug toxicokinetics*. Marcel Dekker, Inc. New York, 1993.
- [24] YACOBI A., SKELLY J.P. and BATRA V.K. *Toxicokinetics and new drug development*, Pergamon Press, 1989.

This page intentionally left blank

This page intentionally left blank

# BSI - British Standards Institution

BSI is the independent national body responsible for preparing British Standards. It presents the UK view on standards in Europe and at the international level. It is incorporated by Royal Charter.

## Revisions

British Standards are updated by amendment or revision. Users of British Standards should make sure that they possess the latest amendments or editions.

It is the constant aim of BSI to improve the quality of our products and services. We would be grateful if anyone finding an inaccuracy or ambiguity while using this British Standard would inform the Secretary of the technical committee responsible, the identity of which can be found on the inside front cover. Tel: +44 (0)20 8996 9000. Fax: +44 (0)20 8996 7400.

BSI offers members an individual updating service called PLUS which ensures that subscribers automatically receive the latest editions of standards.

## Buying standards

Orders for all BSI, international and foreign standards publications should be addressed to Customer Services. Tel: +44 (0)20 8996 9001. Fax: +44 (0)20 8996 7001 Email: [orders@bsigroup.com](mailto:orders@bsigroup.com) You may also buy directly using a debit/credit card from the BSI Shop on the Website <http://www.bsigroup.com/shop>

In response to orders for international standards, it is BSI policy to supply the BSI implementation of those that have been published as British Standards, unless otherwise requested.

## Information on standards

BSI provides a wide range of information on national, European and international standards through its Library and its Technical Help to Exporters Service. Various BSI electronic information services are also available which give details on all its products and services. Contact Information Centre. Tel: +44 (0)20 8996 7111 Fax: +44 (0)20 8996 7048 Email: [info@bsigroup.com](mailto:info@bsigroup.com)

Subscribing members of BSI are kept up to date with standards developments and receive substantial discounts on the purchase price of standards. For details of these and other benefits contact Membership Administration. Tel: +44 (0)20 8996 7002 Fax: +44 (0)20 8996 7001 Email: [membership@bsigroup.com](mailto:membership@bsigroup.com)

Information regarding online access to British Standards via British Standards Online can be found at <http://www.bsigroup.com/BSOL>

Further information about BSI is available on the BSI website at <http://www.bsigroup.com>.

## Copyright

Copyright subsists in all BSI publications. BSI also holds the copyright, in the UK, of the publications of the international standardization bodies. Except as permitted under the Copyright, Designs and Patents Act 1988 no extract may be reproduced, stored in a retrieval system or transmitted in any form or by any means – electronic, photocopying, recording or otherwise – without prior written permission from BSI.

This does not preclude the free use, in the course of implementing the standard, of necessary details such as symbols, and size, type or grade designations. If these details are to be used for any other purpose than implementation then the prior written permission of BSI must be obtained.

Details and advice can be obtained from the Copyright and Licensing Manager. Tel: +44 (0)20 8996 7070 Email: [copyright@bsigroup.com](mailto:copyright@bsigroup.com)

BSI Group  
Headquarters 389  
Chiswick High Road,  
London, W4 4AL, UK  
Tel +44 (0)20 8996 9001  
Fax +44 (0)20 8996 7001  
[www.bsigroup.com/  
standards](http://www.bsigroup.com/standards)